Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Schneider, Andreas ^a,b   Schneider, Markus P ^b,c   Scharnagl, Hubert ^d   Jardine, Alan G ^b   Wanner, Christoph ^a   Drechsler, Christiane ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COLECALCIFEROL; CREATININE; ERYTHROPOIETIN; FERRITIN; GLUCOSE; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; OSTEOCALCIN; PARATHYROID HORMONE; POTASSIUM; TROPONIN T; UREA;

ADULT; AGED; ARTICLE; BODY MASS; FEMALE; HEART FAILURE; HEART RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGE FACTORS; AGED; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SEX FACTORS;

EID: 84875139454     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-67     Document Type: Article

References (23)

1. U S Renal Data System, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD: National Institutes of Health 2011
2. Registry ERA-EDTA, ERA-EDTA Registry 2005 Annual Report Amsterdam, The Netherlands: Academic Medical Center DoMI 2007
3. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW, N Engl J Med 1987 316 2 73 78 10.1056/NEJM198701083160203 3537801
4. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Nephrol Dial Transplant 2004 19 Suppl 2 i1 ii47 15206425
5. USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients. Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW, Contrib Nephrol 1989 76 160 165 discussion 212-168 2684518
6. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, N Engl J Med 2010 363 12 1146 1155 10.1056/NEJMoa1005109 20843249
7. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Rizza GM, Nephrol Dial Transplant 2011 26 8 2641 2648 10.1093/ndt/gfq802 21325348
8. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Lopez-Gomez JM, Portoles JM, Aljama P, Kidney Int Suppl 2008 111 75 S81 19034333
9. An economic evaluation of erythropoiesis-stimulating agents in CKD. Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ, Am J Kidney Dis 2010 56 6 1050 1061 10.1053/j.ajkd.2010.07.015 20932621
10. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, Kiss I, Lakatos P, Marton A, Molnar MZ, Nephron Clin Pract 2010 117 4 373 c378 21071961
11. Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients. Lin CL, Hung CC, Yang CT, Huang CC, Ren Fail 2004 26 3 289 295 10.1081/JDI-120039528 15354979
12. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S, De Simone W, Mandalari A, Brunori G, Amato M, Nephrol Dial Transplant 2006 21 4 991 998 16384825
13. Influence of erythropoiesis-stimulating agents on glycated hemoglobin in nondiabetic kidney diseases at the start of dialysis. Cordeiro AC, Carrero JJ, Barany P, Qureshi AR, Heimburger O, Lindholm B, Stenvinkel P, Am J Nephrol 2011 33 1 17 24 10.1159/000322608 21124022
14. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, N Engl J Med 2005 353 3 238 248 10.1056/NEJMoa043545 16034009
15. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Gunnell J, Yeun JY, Depner TA, Kaysen GA, Am J Kidney Dis 1999 33 1 63 72 10.1016/S0272-6386(99)70259-3 9915269
16. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Barany P, Divino Filho JC, Bergstrom J, Am J Kidney Dis 1997 29 4 565 568 10.1016/S0272-6386(97)90339-5 9100046
17. Pathophysiology of protein-energy wasting in chronic renal failure. Kopple JD, J Nutr 1999 129 Suppl 247S 251S 9915908
18. Wasting and sudden cardiac death in hemodialysis patients: a post Hoc analysis of 4D (Die deutsche diabetes dialyse studie). Drechsler C, Grootendorst DC, Pilz S, Tomaschitz A, Krane V, Dekker F, Marz W, Ritz E, Wanner C, Am J Kidney Dis 2011 58 4 599 607 10.1053/j.ajkd.2011.05.026 21820222
19. Hyporesponsiveness to erythropoietin: causes and management. Elliott J, Mishler D, Agarwal R, Adv Chronic Kidney Dis 2009 16 2 94 100 10.1053/j.ackd.2008.12.004 19233068
20. Results of the European survey on anaemia management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Jacobs C, Frei D, Perkins AC, Nephrol Dial Transplant 2005 20 Suppl 3 ii3 iii24 15824128
21. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF, Clin Nephrol 2003 60 5 335 340 14640239
22. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD, Kidney Int 2008 73 5 630 636 10.1038/sj.ki.5002746 18094675
23. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. Saudan P, Halabi G, Perneger T, Wasserfallen JB, Wauters JP, Martin PY, J Nephrol 2006 19 1 91 96 16523432